Candidosis is a disease of the debilitated and occurs as a consequence of some breakdown in the host immune defenses, which is brought about by an underlying disease. Patients receiving chemotherapy for their primary illness increase their chances of contracting infection by Candida. Modulations of the microbial ligands and complementary host-cell receptors including expression, synthesis, steric changes, surface potentials, or hydrophobicity by various therapeutic modalities may have an important effect on the adhesion process and consequently on pathogenicity. Therapeutic agents that require investigation in relation to their effect on adherence may be divided into two categories drugs that are used for the prevention and control of yeast infection, namely, antifungals and antibacterials, and therapeutic regimes which are generally associated with potentiation of candidosis such as steroids, antibiotics, antineoplastic agents, and X-irradiation. The introduction of newer therapeutic modalities into clinical medicine has been responsible for the dramatic change in the incidence of candidosis.